Non-prescribing of clozapine for outpatients with schizophrenia in real-world settings: The clinicians’ perspectives

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 523 KB, PDF-dokument

Clozapine is the gold standard for treating treatment-resistant schizophrenia although continuously underutilized. Previous surveys of clinicians have found that some of the most frequently cited barriers to clozapine prescribing are related to the blood-monitoring requirements. However, these surveys tend to explore general perspectives and may not reflect the true impact of different barriers in real-world outpatient settings. This study aimed to explore this issue. First, by surveying the clinicians responsible for the treatment of 39 clozapine-eligible, yet clozapine-naive, outpatients with schizophrenia. Then, based on the survey results, explanatory interviews with the participating psychiatrists were conducted and analyzed thematically. The most frequently cited reason for non-prescribing of clozapine was the expected non-compliance with blood-monitoring requirements; however, overall stability and/or severe mental illness was chosen as the most important reason in most patient-cases. The qualitative analysis highlighted the combined impact of standard clinical practice, personal experiences, and organizational constraints on clozapine utility.
OriginalsprogEngelsk
Artikelnummer91
TidsskriftSchizophrenia
Vol/bind9
Udgave nummer1
Antal sider13
ISSN2334-265X
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
This study is part of a PhD project, funded by the Mental Health Services of Region Zealand Psychiatry East, Roskilde, Denmark, The Psychiatric Research Unit, Region Zealand Psychiatry, Slagelse, Denmark, and the Psychiatric Centre Glostrup, Unit for Complicated Schizophrenia, Mental Health Services of The Capital Region of Denmark, in collaboration. Due to the funding by the Psychiatric Research Unit, Region Zealand Psychiatry, the study is partially funded by a private donation favoring patient-oriented research within the region.

Publisher Copyright:
© 2023, The Author(s).

ID: 379036088